ReviewJournal of Cancer2018
Cancer vaccine: learning lessons from immune checkpoint inhibitors.
Review in Journal of Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Erythrocyte-inspired biomaterials for cancer immunotherapy: Integration within the cancer-immunity cycle.Materials today. Bio · 2026Review
- Cancer Vaccines in Genitourinary Malignancies: Current Advances and Future Directions.Vaccines · 2026Review
- Current Landscape of Therapeutic Cancer Vaccines.Methods in molecular biology (Clifton, N.J.) · 2025Review
- A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.ACS nano · 2024Article
- Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer.NPJ genomic medicine · 2024Article
- Senescent cancer cell-derived nanovesicle as a personalized therapeutic cancer vaccine.Experimental & molecular medicine · 2023Article
- Cancer neoantigens as potential targets for immunotherapy.Clinical & experimental metastasis · 2022Review
- Protective and Therapeutic Effects of an IL-15:IL-15Rα-Secreting Cell-Based Cancer Vaccine Using a Baculovirus System.Cancers · 2021Article
- Review
- Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer.International journal of molecular sciences · 2021Review
- Curcumin as an Adjuvant to Cancer Immunotherapy.Frontiers in oncology · 2021Review
- Review
- B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine.Future oncology (London, England) · 2020Review
- Article
- Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Cancer Immunotherapy: Silencing Intracellular Negative Immune Regulators of Dendritic Cells.Cancers · 2019Review
- Is adaptive therapy natural?PLoS biology · 2018Article
- Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).International journal of oncology · 2018Review
- Current status and future directions of cancer immunotherapy.Journal of Cancer · 2018Review
- Potentiating cancer vaccine efficacy in liver cancer.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer vaccines have been exclusively studied all through the past decades, and have made exceptional achievements in cancer treatment. Few cancer vaccines have been approved by the US Food and Drug Administration (FDA), for instance, Provenge, which was approved for the treatment of prostate carcinoma in 2012. Moreover, more recently, T-VEC got approval for the treatment of melanoma. While, the overall therapeutic effects of cancer vaccines have been taken into consideration as below expectations, low antigenicity of targeting antigen and tumor heterogeneity are the two key limiting barriers encountered by the cancer vaccines. Nonetheless, recent developments in cancer immune-therapies together with associated technologies, for instance the unparalleled achievements bagged by immune checkpoint inhibitor based therapies and neo-antigen identification tools, envisage potential improvements in cancer vaccines in respect to the treatments of malignancies. This review brings forth measures for the purpose of refining therapeutic cancer vaccines by learning lessons from the success of PD-1 inhibitor based immune-therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.